Cargando…

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus

Objective: Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus. Methods: As a sub-analysis study of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuhashi, Masato, Sakuma, Ichiro, Morimoto, Takeshi, Higashiura, Yukimura, Sakai, Akiko, Matsumoto, Megumi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538548/ https://www.ncbi.nlm.nih.gov/pubmed/33071982 http://dx.doi.org/10.3389/fendo.2020.575557

Ejemplares similares

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
por: Furuhashi, Masato, et al.
Publicado: (2020)

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2019)

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2020)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2020)

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
por: Ueda, Shinichiro, et al.
Publicado: (2018)

Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells
por: Yamamoto, Tokunori, et al.
Publicado: (2016)

Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study
por: Saito, Norie, et al.
Publicado: (2021)

FABP1 and FABP2 as markers of diabetic nephropathy
por: Tsai, I-Ting, et al.
Publicado: (2020)

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
por: Furuhashi, Masato, et al.
Publicado: (2016)

Expression and enhancement of FABP4 in septoclasts of the growth plate in FABP5-deficient mouse tibiae
por: Bando, Yasuhiko, et al.
Publicado: (2021)

High expression of FABP4 and FABP6 in patients with colorectal cancer
por: Zhang, Yaqin, et al.
Publicado: (2019)

Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters
por: Furuhashi, Masato, et al.
Publicado: (2016)

FABP3, FABP4, and heart rate variability among patients with chronic schizophrenia
por: Hung, Wei-Chin, et al.
Publicado: (2023)

The Interaction of FABP with Kapα
por: Amber-Vitos, Ortal, et al.
Publicado: (2015)

SnapShot: FABP Functions
por: Li, Bing, et al.
Publicado: (2020)

Retinoic acid regulates cell-shape and -death of E-FABP (FABP5)-immunoreactive septoclasts in the growth plate cartilage of mice
por: Bando, Yasuhiko, et al.
Publicado: (2017)

Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages
por: Furuhashi, Masato, et al.
Publicado: (2017)

FABP4 and I-FABP Levels in Pregnant Women Are Associated with Body Mass Index but Not Gestational Diabetes
por: Vorobjova, Tamara, et al.
Publicado: (2022)

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases
por: Furuhashi, Masato, et al.
Publicado: (2015)

Initial studies of the cytoplasmic FABP superfamily
por: Ono, Teruo, et al.
Publicado: (2010)

E-FABP: regulator of immune function
por: Zhang, Yuwen, et al.
Publicado: (2014)

Structural Insights into Mouse H-FABP
por: Wang, Lili, et al.
Publicado: (2022)

Level of FABP3, FABP4, Nt-proBNP and Total Cardiovascular Risk in the Population of Central Kazakhstan
por: Marchenko, Alexandr Borisovich, et al.
Publicado: (2017)

Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria
por: Tanaka, Marenao, et al.
Publicado: (2020)

Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication
por: Furuhashi, Masato, et al.
Publicado: (2022)

Cigarette smoke inhibits LPS-induced FABP5 expression by preventing c-Jun binding to the FABP5 promoter
por: Rao, Deviyani, et al.
Publicado: (2017)

Fatty Acid Binding Proteins FABP9 and FABP10 Participate in Antibacterial Responses in Chinese Mitten Crab, Eriocheir sinensis
por: Cheng, Lin, et al.
Publicado: (2013)

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)
por: Tang, Zhiyuan, et al.
Publicado: (2016)

Differential regulation of hypoxanthine and xanthine by obesity in a general population
por: Furuhashi, Masato, et al.
Publicado: (2020)

Fabp4-CreER lineage tracing revealstwo distinctive coronary vascular populations
por: He, Lingjuan, et al.
Publicado: (2014)

Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study
por: Fujita, Yuko, et al.
Publicado: (2022)

Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals
por: Tanaka, Marenao, et al.
Publicado: (2022)

Unconventional secretion of FABP4 by endosomes and secretory lysosomes
por: Villeneuve, Julien, et al.
Publicado: (2018)

Clinical significance of urinary L-FABP in the emergency department
por: Suzuki, Ginga, et al.
Publicado: (2019)

A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update
por: Li, Hang-Long, et al.
Publicado: (2021)

Expression Profiles and Prognostic Value of FABPs in Colorectal Adenocarcinomas
por: Prayugo, Fidelia Berenice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i6jrnodois34k0lsj4pudmphui